Stories tagged science & research.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
The Trump administration plans to cancel enrollment in Affordable Care Act plans for more than 760,000 people as part of its crackdown on fraud, waste and abuse.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
The partnership builds on OpenEvidence's vision to develop “medical super-intelligence” based on agentic artificial intelligence, or a system of AI agents that can be subspecialists in clinical areas.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Healthcare is entering an AI era, and the industry needs a fundamentally different architecture designed for AI from the start, Oracle Health executives said Wednesday.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Stick with this tracker for the latest layoff and workforce updates from across healthcare.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
The new Pelago Behavioral Health Platform means co-occurring conditions can be assessed and treated in a single plan. Behavioral addiction programming includes gambling, gaming and binge eating
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Stay up-to-date with this tracker for the latest RHTP funding announcements and disclosures.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
The virtual startup leverages labs with health coaches and dietitians to address the biological and metabolic health needs of individuals in recovery.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Oura, the smart ring maker and health tracking company, filed to go public on Thursday to fuel its next phase of growth as it aims to build an artificial intelligence-powered health platform.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Roche has reported a phase 3 win for sefaxersen in kidney disease, teeing up talks with regulators about the path to approval for the Ionis-partnered, would-be blockbuster candidate.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
The FDA gave the green light to a first and only sirolimus drug-eluting balloon designed by Cordis to treat coronary in-stent restenosis.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Senator Todd Young (R-IN), chairman of the National Security Commission on Emerging Biotechnology, told Fierce why he's concerned about the growth of China's biopharma industry.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
As an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a preclinical radioligand therapy from a specialist Chinese biotech.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for people with type 2 diabetes and overweight or obesity.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an unblemished safety profile for its potential first-in-class candidate, miv-cel.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Celldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in milestones.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
GSK has been operating a strategy of “balancing the West and the East” since the Big Pharma’s eyes were opened to the potential of licensing drugs from China two years ago, according to an executive.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Iambic Therapeutics is maintaining the momentum generated by its recent mega round and Big Pharma partnerships by gearing up to go public.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status as a hotbed for innovative R&D.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich ataxia (FA) portfolio while locking in three strategic collaborations to support its lead asset.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
The Department of War has awarded Flagship Pioneering $47 million to develop medical countermeasure technologies against emerging threats.
Fierce Biotech / Fierce Healthcare / MedCity / GEN
Medtech startup Anaconda Biomed has hauled in $53 million to help finish off work on a pivotal trial for its endovascular project.